Korean Drug Co Stock Working Capital
| 014570 Stock | KRW 4,270 90.00 2.06% |
Korean Drug Co fundamentals help investors to digest information that contributes to Korean Drug's financial success or failures. It also enables traders to predict the movement of Korean Stock. The fundamental analysis module provides a way to measure Korean Drug's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Korean Drug stock.
Korean |
Korean Drug Co Company Working Capital Analysis
Korean Drug's Working Capital is a measure of company efficiency and operating liquidity. The working capital is usually calculated by subtracting Current Liabilities from Current Assets. It is an important indicator of the firm ability to continue its normal operations without additional debt obligations. .
More About Working Capital | All Equity Analysis
Working Capital | = | Current Assets | - | Current Liabilities |
Current Korean Drug Working Capital | 33.63 B |
Most of Korean Drug's fundamental indicators, such as Working Capital, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Korean Drug Co is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Working Capital can be positive or negative, depending on how much of current debt the company is carrying on its balance sheet. In general terms, companies that have a lot of working capital will experience more growth in the near future since they can expand and improve their operations using existing resources. On the other hand, companies with small or negative working capital may lack the funds necessary for growth or future operation. Working Capital also shows if the company has sufficient liquid resources to satisfy short-term liabilities and operational expenses.
| Competition |
In accordance with the company's disclosures, Korean Drug Co has a Working Capital of 33.63 B. This is much higher than that of the Healthcare sector and significantly higher than that of the Pharmaceuticals industry. The working capital for all Republic of Korea stocks is significantly lower than that of the firm.
Korean Working Capital Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Korean Drug's direct or indirect competition against its Working Capital to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Korean Drug could also be used in its relative valuation, which is a method of valuing Korean Drug by comparing valuation metrics of similar companies.Korean Drug is currently under evaluation in working capital category among its peers.
Korean Fundamentals
| Return On Equity | 15.3 | |||
| Return On Asset | 0.0702 | |||
| Profit Margin | 0.11 % | |||
| Operating Margin | 0.14 % | |||
| Current Valuation | 94.01 B | |||
| Shares Outstanding | 11 M | |||
| Shares Owned By Insiders | 50.19 % | |||
| Shares Owned By Institutions | 0.28 % | |||
| Price To Earning | 55.67 X | |||
| Price To Sales | 1.11 X | |||
| Revenue | 74.47 B | |||
| Gross Profit | 28.69 B | |||
| EBITDA | 11.14 B | |||
| Net Income | 9.04 B | |||
| Cash And Equivalents | 4.68 B | |||
| Cash Per Share | 980.50 X | |||
| Total Debt | 15 M | |||
| Debt To Equity | 0.10 % | |||
| Current Ratio | 6.69 X | |||
| Cash Flow From Operations | 8.81 B | |||
| Number Of Employees | 14 | |||
| Beta | 0.25 | |||
| Market Capitalization | 84.81 B | |||
| Total Asset | 88.61 B | |||
| Retained Earnings | 40.74 B | |||
| Working Capital | 33.63 B | |||
| Current Asset | 40.97 B | |||
| Current Liabilities | 7.34 B | |||
| Annual Yield | 0.01 % | |||
| Net Asset | 88.61 B |
About Korean Drug Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Korean Drug Co's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Korean Drug using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Korean Drug Co based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Pair Trading with Korean Drug
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Korean Drug position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Korean Drug will appreciate offsetting losses from the drop in the long position's value.Moving together with Korean Stock
Moving against Korean Stock
The ability to find closely correlated positions to Korean Drug could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Korean Drug when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Korean Drug - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Korean Drug Co to buy it.
The correlation of Korean Drug is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Korean Drug moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Korean Drug moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Korean Drug can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Other Information on Investing in Korean Stock
Korean Drug financial ratios help investors to determine whether Korean Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Korean with respect to the benefits of owning Korean Drug security.